利利公司扩大肥胖市场的统治地位, Lilly expands obesity market dominance with new treatments and superior weight-loss drug.

伊利莉正在扩大其肥胖市场的优势, Eli Lilly is expanding its obesity market dominance by developing a diversified portfolio of new treatments. 它的首选药物,雷塔胺 (retatrutide),与目前的Zepbound相比显示出更好的减肥效果. 针对严重肥胖患者. Its top pipeline candidate, retatrutide, shows superior weight loss results compared to its current drug Zepbound and targets patients with severe obesity. 公司还推出一种口服减肥药, Additionally, the company is advancing an oral weight-loss pill to cater to those preferring non-injectable options.